Frailty

🩺What is Frailty?

The ECOG Performance Status (also known as the WHO or Zubrod score) was developed by the Eastern Cooperative Oncology Group in 1982 as a simple, reproducible method for quantifying the functional status of cancer patients. It has since become one of the most widely used performance status scales in oncology worldwide. The scale ranges from 0 (fully active) to 5 (dead) and provides a standardized language for describing a patient's level of functioning. ECOG PS is a critical component of oncology treatment decision-making — it is used to determine chemotherapy eligibility, predict treatment tolerance, estimate prognosis, and define clinical trial inclusion and exclusion criteria. Nearly all major cancer clinical trials use ECOG PS as a stratification factor and eligibility criterion. The scale has been validated across multiple cancer types and treatment settings, consistently demonstrating that ECOG PS is one of the strongest independent predictors of survival. A systematic review of 34 studies involving over 20,000 patients found that performance status was independently predictive of survival in 87% of studies, with each one-point increase in ECOG PS associated with a 20-30% increase in mortality risk. The scale is also used beyond oncology in geriatrics, palliative care, and general medicine for assessing functional capacity and guiding care decisions. A key strength of ECOG PS is its simplicity — it can be assessed in less than 30 seconds with a single question. However, limitations include inter-observer variability and the subjective nature of the assessment. Alternative performance status measures include the Karnofsky Performance Scale (KPS), which provides a more granular 11-point scale (0-100) but correlates well with ECOG PS (conversion: KPS 100 = ECOG 0, KPS 80-90 = ECOG 1, KPS 60-70 = ECOG 2, KPS 40-50 = ECOG 3, KPS 10-30 = ECOG 4, KPS 0 = ECOG 5).

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Frailty:

• ECOG Performance Status Scale

  The ECOG Performance Status (ECOG PS) scale, developed by the Eastern Cooperative Oncology Group, is a widely used tool for assessing a patient's functional capacity and ability to perform daily activities. It is a standard measure in oncology for treatment decision-making and clinical trial eligibility.

• Karnofsky Performance Scale

  The Karnofsky Performance Scale (KPS) is a widely used 11-point scale (0-100) that quantifies a patient's functional status and ability to perform activities of daily living. It is commonly used in oncology, palliative care, and geriatrics.

• G8 — Geriatric 8 Screening

  The Geriatric 8 (G8) screening tool is an 8-item validated instrument designed to identify older patients who may benefit from comprehensive geriatric assessment (CGA). It is widely used in geriatric oncology to detect frailty.

• MNA-SF — Mini Nutritional Assessment (Short Form)

  The Mini Nutritional Assessment Short Form (MNA-SF) is a validated 6-item screening tool for malnutrition risk in older adults. It is widely used in geriatric medicine, long-term care, and hospital settings to identify patients requiring nutritional intervention.

🧬Diagnostic Logic & Scoring Breakdown

The ECOG PS is determined through a structured clinical assessment of the patient's ability to perform daily activities. Grade 0: Fully active, no restrictions from baseline. Grade 1: Restricted in strenuous activity but ambulatory and able to do light work. Grade 2: Ambulatory >50% of waking hours, capable of self-care but unable to work. Grade 3: Limited self-care, confined to bed/chair >50%. Grade 4: Completely disabled, confined to bed/chair. Grade 5: Dead. For oncology patients, ECOG PS 0-1 is generally required for most chemotherapy regimens. ECOG PS ≥2 may indicate treatment modification or palliative approach.

📢Clinical Significance & Implications

ECOG PS is one of the most important prognostic tools in oncology, serving as a standard criterion for clinical trial eligibility and treatment decision-making. Each one-point increase is associated with 20-30% higher mortality risk across multiple cancer types. ECOG PS has been validated in lung cancer (where patients with ECOG 0-1 have median survival nearly double that of ECOG 2+), breast cancer, colorectal cancer, and hematologic malignancies. Beyond prognosis, ECOG PS guides treatment intensity: patients with ECOG 0-1 are candidates for aggressive multimodality therapy, ECOG 2 may require dose modification, and ECOG 3-4 typically receive best supportive care or palliative treatment only.

💡 Clinical Assessment Scenario Example

A 62-year-old woman with metastatic breast cancer presents for initial chemotherapy consultation. She reports that she is able to perform all her usual activities including grocery shopping, light housework, and walking without limitation. She works part-time as a receptionist. She has no symptoms at rest and experiences only mild fatigue with strenuous activity. She spends 100% of her waking hours out of bed. ECOG Performance Status: Grade 0 — Fully active. She is an excellent candidate for standard combination chemotherapy.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Frailty:

🔗Related Diseases & Conditions

These conditions are clinically associated with Frailty through shared risk-scoring calculators and assessment tools:

• Cancer — General Oncology
• Malnutrition
• Sarcopenia

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Confusing ECOG PS with Karnofsky Performance Scale (KPS)

  ✅ Correction: ECOG PS is a 6-point scale (0-5) while KPS is an 11-point scale (0-100). Both measure functional status but use different scoring systems. Common conversions: KPS 100 = ECOG 0, KPS 80-90 = ECOG 1, KPS 60-70 = ECOG 2, KPS 40-50 = ECOG 3, KPS 10-30 = ECOG 4, KPS 0 = ECOG 5. ECOG PS is simpler and more commonly used in clinical trials.

• ❌ Mistake: Assigning ECOG PS based on age or comorbidities rather than actual functional status

  ✅ Correction: ECOG PS assesses the patient's actual current functional capacity, not their age or list of comorbidities. An 80-year-old can have ECOG 0 if fully active, while a 50-year-old with significant functional limitation may be ECOG 3. The assessment should be based on what the patient can actually do, not what would be expected for their age or diagnosis.

• ❌ Mistake: Using ECOG PS as the sole determinant of treatment decisions

  ✅ Correction: While ECOG PS is a critical tool, treatment decisions should incorporate the full clinical picture including cancer type and stage, organ function, patient preferences, geriatric assessment (for older adults), frailty assessment, and social support. ECOG PS should complement, not replace, comprehensive clinical judgment.

• ❌ Mistake: Using KPS and ECOG PS interchangeably without proper conversion

  ✅ Correction: KPS and ECOG PS are different scales with different granularity. When converting: KPS 100 = ECOG 0, KPS 80-90 = ECOG 1, KPS 60-70 = ECOG 2, KPS 40-50 = ECOG 3, KPS 10-30 = ECOG 4, KPS 0 = ECOG 5. Never use them interchangeably without acknowledging the conversion.

• ❌ Mistake: Assigning KPS based on treatment intent rather than actual function

  ✅ Correction: KPS should reflect the patient's actual current functional status, not the clinician's treatment plan. A patient receiving palliative chemotherapy can have KPS 80 if they are functioning well, while a patient receiving curative therapy may have KPS 50 due to treatment side effects. The KPS score describes function, not treatment intent.

• ❌ Mistake: Using G8 as a substitute for comprehensive geriatric assessment (CGA)

  ✅ Correction: G8 is a screening tool, not a comprehensive assessment. Abnormal G8 (≤14) triggers referral for CGA, not a diagnosis of frailty.

• ❌ Mistake: Not knowing patient's weight loss amount and scoring as 0

  ✅ Correction: If weight loss is unknown, score as 1 point ("does not know"). Do not default to 0 or 3. Weight estimation by family or records may help.

• ❌ Mistake: Using MNA-SF without the full MNA follow-up for at-risk patients

  ✅ Correction: MNA-SF is a screening tool. Patients scoring 8-11 (at risk) should receive the full 18-item MNA assessment for comprehensive evaluation.

• ❌ Mistake: Assuming normal MNA-SF rules out all nutritional problems

  ✅ Correction: MNA-SF screens for malnutrition risk, not all nutritional disorders. Patients with specific nutritional concerns (e.g., vitamin deficiencies, sarcopenia) may need additional evaluation even with normal MNA-SF.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Frailty; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References